 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
4 News |  |
- | MDG1011 / Medigene
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov) - Feb 15, 2023
P1/2, N=9, Terminated, Sponsor: Medigene AG
N=92 --> 9 | Trial completion date: Apr 2024 --> Jul 2022 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Jun 2022; The clinical trial is terminated after the completion of phase I without moving to Phase II.
- MD 101 / MaimoniDex RA
EFFECT OF PROBIOTICS TREATMENT ON PHYSICAL AND MENTAL ASPECTS FOR PATIENTSWITH CORONARY ARTERY DISEASE: A META-ANALYSIS (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4118;
Our findings highlight the probiotics treatment for patients with CAD, probiotics treatment can not only improve the physical but also mental aspects. It has a positive therapeutic effect on the treatment of CAD.
- || MD 101 /
Review, Journal: Telerehabilitation improves physical function and reduces dyspnoea in people with COVID-19 and post-COVID-19 conditions: a systematic review. (Pubmed Central) - Apr 28, 2022
It has a positive therapeutic effect on the treatment of CAD. Telerehabilitation may improve functional capacity, dyspnoea, performance and physical components of quality of life and does not substantially increase adverse events.
- || MD 101 /
Retrospective data, Review, Journal: Is Piezocision effective in accelerating orthodontic tooth movement: A systematic review and meta-analysis. (Pubmed Central) - Jul 16, 2020
Low quality evidence suggests that piezocision is an effective surgical procedure in accelerating the rate of canine retraction in the first two months and reducing the treatment duration. However, this effect appears to be clinically insignificant.
- || MDG1011 / Medigene
Trial completion date, Trial primary completion date: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov) - Mar 6, 2019
P1/2, N=92, Recruiting, Sponsor: Medigene AG
However, this effect appears to be clinically insignificant. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Aug 2019 --> Aug 2020
- ||||| MDG1011 / Medigene
New P1/2 trial: TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms (clinicaltrials.gov) - Apr 19, 2018
P1/2, N=92, Recruiting, Sponsor: Medigene AG